Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Lidocaine Patch 1.8% vs Lidoderm in Healthy Subjects
NCT04144192Phase 1Completed
- Sponsor
- Scilex Holding
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of lidocaine 10% oropharyngeal spray in postherpetic neuralgia (PHN) (2 arms), sponsored by Scilex Holding. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time 0 to Time 48 hours and 1 more. Started Apr 2014; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT04144192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144192.